Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (45)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Bykov, V. J.N.
Right arrow Articles by Wiman, K. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bykov, V. J.N.
Right arrow Articles by Wiman, K. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 23, No. 12, 2011-2018, December 2002
© 2002 Oxford University Press

CANCER BIOLOGY

Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database

Vladimir J.N. Bykov, Natalia Issaeva, Galina Selivanova and Klas G. Wiman1

Karolinska Institutet, Department of Oncology–Pathology, Cancer Center Karolinska (CCK), R8:04 Karolinska Hospital, SE-171 76 Stockholm, Sweden

We recently identified PRIMA-1 as a low molecular weight compound that restores tumor suppressor function to mutant p53 proteins and has anti-tumor activity in vivo (1). Here we report the statistical analysis of the effect of PRIMA-1 on a panel of human tumor cell lines using information available in a database at the Developmental Therapeutics Program of the National Cancer Institute (NCI). We extracted growth inhibition profiles for PRIMA-1 and 44 known anticancer agents, p53 status of cell lines, population doubling time, and level of p53 protein expression from the NCI database. The data were analyzed by linear regression, Wilcoxon matched pairs test, and cluster analysis. In a subset of human cell lines derived from colon, ovarian, renal, and non-small cell lung cancer and melanoma, the level of mutant p53 expression correlated with cell population doubling time, r = -0.53, P = 0.018. The GI50 values for PRIMA-1 correlated with levels of mutant p53, r = -0.75, P = 0.0002. PRIMA-1 showed a statistically significant preference at P = 0.04 for growth inhibition of tumor cell lines expressing mutant p53 as compared with lines expressing wild-type p53. In contrast, none of several known anticancer drugs showed such preference. PRIMA-1 inhibited the growth of cell lines derived from various human tumor types in a mutant p53-dependent manner. This distinguishes PRIMA-1 from known anticancer drugs and supports the idea that PRIMA-1 can serve as a lead for the development of novel therapeutic compounds.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
H. Shi, J. M.R. Lambert, A. Hautefeuille, V. J.N. Bykov, K. G. Wiman, P. Hainaut, and C. C. de Fromentel
In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249
Carcinogenesis, July 1, 2008; 29(7): 1428 - 1434.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Widodo, K. Kaur, B. G. Shrestha, Y. Takagi, T. Ishii, R. Wadhwa, and S. C. Kaul
Selective Killing of Cancer Cells by Leaf Extract of Ashwagandha: Identification of a Tumor-Inhibitory Factor and the First Molecular Insights to Its Effect
Clin. Cancer Res., April 1, 2007; 13(7): 2298 - 2306.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. Lacroix, R.-A. Toillon, and G. Leclercq
p53 and breast cancer, an update.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 293 - 325.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. S. Ricci and W.-X. Zong
Chemotherapeutic approaches for targeting cell death pathways.
Oncologist, April 1, 2006; 11(4): 342 - 357.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. J. N. Bykov, N. Issaeva, N. Zache, A. Shilov, M. Hultcrantz, J. Bergman, G. Selivanova, and K. G. Wiman
Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs
J. Biol. Chem., August 26, 2005; 280(34): 30384 - 30391.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Li, Y. Mao, P. W. Brandt-Rauf, A. C. Williams, and R. L. Fine
Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway
Mol. Cancer Ther., June 1, 2005; 4(6): 901 - 909.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
M. Lun, P. L. Zhang, N. Siegelmann-Danieli, T. M. Blasick, and R. E. Brown
Intracellular Inhibitory Effects of Velcade Correlate with Morphoproteomic Expression of Phosphorylated-Nuclear Factor-{kappa}B and p53 in Breast Cancer Cell Lines
Ann. Clin. Lab. Sci., January 1, 2005; 35(1): 15 - 24.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. A. Williams and D. J. McConkey
The Proteasome Inhibitor Bortezomib Stabilizes a Novel Active Form of p53 in Human LNCaP-Pro5 Prostate Cancer Cells
Cancer Res., November 1, 2003; 63(21): 7338 - 7344.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.